Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months

BACKGROUND: Development and deployment of an effective malaria vaccine would complement existing malaria control measures. A blood stage malaria vaccine candidate, Merozoite Surface Protein-3 (MSP3), produced as a long synthetic peptide, has been shown to be safe in non-immune and semi-immune adults...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Lusingu, John PA, Gesase, Samwel, Msham, Salum, Francis, Filbert, Lemnge, Martha, Seth, Misago, Sembuche, Samwel, Rutta, Acleus, Minja, Daniel, Segeja, Method D, Bosomprah, Samuel, Cousens, Simon, Noor, Ramadhani, Chilengi, Roma, Druilhe, Pierre
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2009
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2720982/
https://ncbi.nlm.nih.gov/pubmed/19607731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2875-8-163
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia